4-Iodobiphenyl | CAS:1591-31-7

We serve 4-Iodobiphenyl CAS:1591-31-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
4-Iodobiphenyl

Chemical Name:   4-Iodobiphenyl
CAS.NO: 1591-31-7
Synonyms: 1,1‘-Biphenyl, 4-iodo-
 
Molecular Formula: C12H9I
Molecular Weight: 280.10400
 
Physical and Chemical Properties:
Density: 1.584 g / cm3
Boiling point: 322.7ºC at 760 mmHg
Melting point: 110-114 ° C
Flash point: 145.8ºC
Refractive index: 1.64
 
Specification:
Appearance:White or light yellow crystal
Purity:>99.5%
 
Packing:25kg / cardboard drum, can also be packaged according to customer requirements
Storage:Store in a cool, dry, well-ventilated warehouse. Keep away from fire and heat sources. Protect from direct sunlight. Packaging is sealed. It should be stored separately from acids and edible chemicals.
Application: Applicationd as OLED intermediate



Contact us for information like 4-Iodobiphenyl chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,1‘-Biphenyl, 4-iodo- physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Iodobiphenyl Use and application,4-Iodobiphenyl technical grade,usp/ep/jp grade.


Related News: Slow business: Due to fear — and travel warnings — fewer people want to travel to China.Methyl 4-amino-5-(ethylsulfonyl)-2-methoxybenzoate manufacturer In addition, with the increase of environmental protection pressure, nearly one hundred Beijing pharmaceutical companies have gathered in the Bohai Bay, and the raw material drug base in northern China has taken shape.4-Chloro-2-methylpyridine supplier In addition, with the increase of environmental protection pressure, nearly one hundred Beijing pharmaceutical companies have gathered in the Bohai Bay, and the raw material drug base in northern China has taken shape.(3R,4S)-1-t-Boc-3-[(triethylsilyl)oxy]-4-phenyl-2-azatidinone vendor Large pharmaceutical companies are investing a disproportionately large amount of annual revenue in research and development (R&D), according to GlobalData’s Company Financials database.Large pharmaceutical companies are investing a disproportionately large amount of annual revenue in research and development (R&D), according to GlobalData’s Company Financials database.